Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of an aggressive form of pancreatic cancer.
UNSW Sydney’s Centre for Molecular Oncology will partner with not-for-profit cancer genomics leader Omico to deliver the national precision oncology program PrOSPeCT.